Low-dose reserpine/thiazide combination in first-line treatment of hypertension: Efficacy and safety compared to an ACE-inhibitor

Blood Pressure

Volumn 6, Issue 5, 1997, Pages 299-306

  Griebenow, Reinhard ^a   Pittrow, David Bernhard ^b,e   Weidinger, Gottfried ^b   Mueller, Edgar ^e   Mutschler, Ernst ^c   Welzel, Dieter ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Department of Clinical Research   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Clopamide; Combination therapy; Enalapril; First line treatment; Hypertension; Reserpine

Indexed keywords

CLOPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; RESERPINE; THIAZIDE DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VERTIGO;

EID: 0030762685     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.3109/08037059709062086     Document Type: Article

References (30)

1. Fingl E, Woodbury DM. General principles. In: Goodman LS, Gilman A, eds. The pharmacological basis of therapeutics. 4th Ed. New York: Macmillan, 1970: 24-5.
2. Oster JR, Epstein M. Fixed-dose combination medications for the treatment of hypertension: a critical review. J Clin Hypertens 1987; 3: 278-93.
3. Dengler HJ, Lasagna L. Report of a workshop on fixed-ratio drug combinations. Eur J Clin Pharmacol 1975; 8: 149-54.
4. Fagan TC. Remembering the lessons of basic pharmacology. Arch Intern Med 1994; 154: 1430-1.
5. MacConnachie AM, Maclean D. Low dose combination antihypertensive therapy. Additional efficacy without additional adverse effects? Drug Safety 1995; 12(2): 85-90.
6. Veterans Administration Cooperative Study on Antihypertensive Agents. Effect of treatment on morbidity in hypertension. I: Results for in-patients with diastolic blood pressure averaging 90 through 114mmHg. JAMA 1970; 213: 1143-52.
7. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk changes and mortality results. JAMA 1982; 248(12): 1465-77.
8. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in older persons with Isolated Systolic Hypertension. JAMA 1991; 265: 3255-64.
9. Kostis JB, Berge KG, Davis BR, Hawkins CM, Probstfield J for the SHEP Cooperative Research Group. Effect of atenolol and reserpine on selected events in the Systolic Hypertension in the Elderly Program (SHEP). Am J Hypertens 1995; 8: 1147-53.
10. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program: I. Reductions in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242: 2562-71.
11. Hypertension Detection and Follow-up Program Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-Up Program. JAMA 1988; 259: 2113-22.
12. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens 1992; 5: 207-9.
13. Henry D. Comparing treatments. Br Med J 1995; 310: 1279.
14. Brunner HE, Ménard J, Waeber B, et al. Editorial review: treating the individual hypertensive patient: considerations of dose, sequential monotherapy and drug combinations. J Hypertens 1990; 8: 3-11.
15. Materson BJ, Cushman WC, Goldstein G, et al. Treatment of hypertension in the elderly. I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study. Hypertension 1990; 15: 348-60.
16. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study: a randomized, placebo-controlled trial of a nutritional regimen along with various drug monotherapies. Arch intern Med 1991; 151: 1413-23.
17. Pittrow DB, Krönig B, Kirch W, Weidinger G. Evaluation of reserpine and clopamide alone or in combination for first-line treatment of hypertension. Am J Hypertens 1996; 6(5): part II.
18. Kennedy RL. The dose-response relationship with angiotensin converting enzyme inhibitors: effects on blood pressure and biochemical parameters. J Hypertens 1992; 10(5): S3-11.
19. Bergstrand R, Herlitz H, Johansson S, et al. Effective dose range of enalapril in mild to moderate essential hypertension. Br J Clin Pharmacol 1985; 19: 605-11.
20. Shoback DM, Williams GH, Swartz SL, Davies RO, Hollenberg NK. Time course and effect of sodium intake on vascular and hormonal responses to enalapril (MK 421) in normal subjects. J Cardiovasc Pharmacol 1983; 5(6): 1010-8.
21. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-50.
22. Freis ED. Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med 1954; 251; 1006-8.
23. Muller JC, Pryor WW, Gibbons JE, Orgain ES. Depression and anxiety occuring rauwolfia therapy. JAMA 1955; 159: 836-9.
24. Participating Veterans Administration Medical Centers. Low doses versus standard dose of reserpine. JAMA 1982; 248(19): 2471-7.
25. Goldstein G, Materson BJ, Cushman WC, et al. Treatment of hypertension in the elderly. II. Cognitive and behavioral function - results of a Department of Veterans Affairs Cooperative Study. Hypertension 1990; 15: 361-9.
26. Annual report on adverse drug events 1993. Drug Monitoring Center. Basel: Sandoz Ltd, 1993.
27. Hypertension Detection and Follow-Up Program Cooperative Group: five-year findings of the Hypertension Detection and follow-Up Program: prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension 1985; 7: 105-12.
28. Horn HJ, Detmar K, Pittrow DB, et al. Regression einer Linksventrikulären Hypertrophie unter Kombinationstherapie mit Reserpin und Diuretika. Kardiol 1996; 85(S5): 40.
29. Lederle FA, Applegate WB, Grimm RH. Reserpine and the medical market place. Arch Intern Med 1993; 153: 705-6.
30. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacological management of hypertension in the United States. Arch Intern Med 1995; 155: 829-37.